Medivir: Simeprevir Has Been Approved in the USA as a New Treatment for Hepatitis C

27-11-2013 Business Wire HealthComments (0)

Antibiotics and Infectious diseasesMedivirPharmaceuticalsimeprevir

Medivir AB (OMX: MVIR) today announced that U.S. Food and Drug Administration (FDA) has approved simeprevir for the treatment of chronic hepatitis C (CHC) genotype 1 infection, in combination with peginterferon alfa and ribavirin in adults with compensated liver disease, including cirrhosis, who are treatment-naïve or who have failed previous interferon therapy (pegylated or non-pegylated) with ribavirin. “The USA approval is a large and important mi

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top